Dr. Douglas Dieterich: “HIV No Bar to HCV Therapy with New Agents”
New drugs for hepatitis C mean HIV co-infection is no longer a barrier to successful HCV treatment, according to researchers at The Mount Sinai Hospital. “Three studies using different medications in co-infected patients all found cure rates similar to the same drugs in people who had only HCV,” said Douglas Dieterich, MD, Professor of Medicine (Liver Diseases) at the Icahn School of Medicine at Mount Sinai.. The rate of cure in all three studies was "exactly the same in co-infected patients as they are in mono-infected patients,” said Dr. Dieterich. Learn more